Northwest Biotherapeutics Inc., of Bethesda, Md., said it would hold a registered direct offering with gross proceeds of about $5 million, which will be used in connection with upcoming phase II trials to test Dcvax-Direct for the potential treatment of inoperable solid tumor cancers.